Payment overview · 2025
General Payments
$371.68
20 reported records · 12 companies
Healthcare provider profile · identity verified
Kristen Lynette Stapleton, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · RICHLANDS, VA · NPI 1932745379
Verified facts
What the public records show
CMS Open Payments records show Kristen Lynette Stapleton, FNP-C received $371.68 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 428 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.78 | 21.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.80 | 13.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.43 | 12.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.49 | 10.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.79 | 8.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.19 | 6.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $19.18 | 5.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.91 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.79 | 4.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.68 | 4.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.16 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.48 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $371.68 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.80 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.79 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 135 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
135 | 36 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
428 | 95 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
86 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 722 | 203 |
| Levothyroxine Sodium | Levothyroxine Sodium | 660 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 141 |
| Omeprazole | Omeprazole | 565 | 120 |
| Lisinopril | Lisinopril | 548 | 136 |
| Furosemide | Furosemide | 458 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 445 | 129 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 445 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 442 | 117 |
| Eliquis | Apixaban | 428 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 388 | 95 |
| Gabapentin | Gabapentin | 372 | 62 |
| Montelukast Sodium | Montelukast Sodium | 356 | 72 |
| Metformin Hcl | Metformin Hcl | 312 | 66 |
| Simvastatin | Simvastatin | 303 | 62 |
| Alprazolam | Alprazolam | 300 | 34 |
| Carvedilol | Carvedilol | 297 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 294 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 60 |
| Potassium Chloride | Potassium Chloride | 258 | 58 |
| Valsartan | Valsartan | 253 | 69 |
| Warfarin Sodium | Warfarin Sodium | 239 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 233 | 62 |
| Ezetimibe | Ezetimibe | 220 | 48 |
| Losartan Potassium | Losartan Potassium | 210 | 63 |
| Meloxicam | Meloxicam | 200 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 37 |
| Famotidine | Famotidine | 169 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 159 | 47 |
| Buspirone Hcl | Buspirone Hcl | 150 | 31 |
| Allopurinol | Allopurinol | 149 | 31 |
| Sertraline Hcl | Sertraline Hcl | 138 | 34 |
| Farxiga | Dapagliflozin Propanediol | 135 | 36 |
| Celecoxib | Celecoxib | 128 | 28 |
| Lorazepam | Lorazepam | 125 | 17 |
| Tramadol Hcl | Tramadol Hcl | 121 | 32 |
| Pregabalin | Pregabalin | 120 | 16 |
| Clonazepam | Clonazepam | 115 | 14 |
| Glimepiride | Glimepiride | 112 | 22 |
| Atenolol | Atenolol | 111 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 17 |
| Mirtazapine | Mirtazapine | 99 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 16 |
| Azithromycin | Azithromycin | 92 | 77 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 22 |
| Entresto | Sacubitril/Valsartan | 86 | 25 |
| Synthroid | Levothyroxine Sodium | 82 | 14 |
| Chlorthalidone | Chlorthalidone | 81 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 57 |
| Methylprednisolone | Methylprednisolone | 80 | 68 |
| Ibuprofen | Ibuprofen | 79 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 79 | 21 |
| Ozempic | Semaglutide | 78 | 15 |
| Trazodone Hcl | Trazodone Hcl | 78 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 13 |
| Januvia | Sitagliptin Phosphate | 72 | 11 |
| Nitroglycerin | Nitroglycerin | 68 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 12 |
| Spironolactone | Spironolactone | 63 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 11 |
| Jardiance | Empagliflozin | 61 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 12 |
| Linzess | Linaclotide | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | suppressed |
| Prednisone | Prednisone | 54 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 18 |
| Glipizide | Glipizide | 52 | 17 |
| Trintellix | Vortioxetine Hydrobromide | 49 | suppressed |
| Digoxin | Digoxin | 48 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | 16 |
| Alendronate Sodium | Alendronate Sodium | 46 | 18 |
| Ibu | Ibuprofen | 45 | 14 |
| Mounjaro | Tirzepatide | 44 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 14 |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 26 |
| Baclofen | Baclofen | 42 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | suppressed |
| Metolazone | Metolazone | 41 | 14 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 16 |
| Brilinta | Ticagrelor | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Torsemide | Torsemide | 38 | 11 |
| Nystatin | Nystatin | 37 | 15 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Kerendia | Finerenone | 36 | suppressed |
| Pentoxifylline | Pentoxifylline | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Colchicine | Colchicine | 34 | 13 |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Irbesartan | Irbesartan | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Diazepam | Diazepam | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | 11 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Cefaclor | Cefaclor | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $371.68 · 20 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, CAMZYOS, CAPLYTA, CREON, FARXIGA, JARDIANCE, Kerendia, LEQVIO, LINZESS, LifeVest, MOUNJARO, Ozempic, REPATHA, Wegovy, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error